ArticleAmerican journal of cancer research2015

Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer.

Choong-Kun Lee et al.PubMed ↗Full text ↗

No numbers read from the abstract.